ImmunotherapyImmune checkpoint inhibitorNon-small cell lung cancerPaclitaxel liposome (Lipusu) is known to be effective in non-small cell lung cancer (NSCLC) as first-line treatment. This study aimed to evaluate the effectiveness and safety of paclitaxel liposome based chemotherapy plus PD-1/PD-L1...
Patients had not undergone immunotherapy, chemotherapy, hormone therapy or radiotherapy before specimen collection. The clinical stage and histological grades were based on the International Federation of Gynecology and Obstetrics staging. Tissue samples were snap frozen in liquid nitrogen and stored at ...
"We put the two concepts together and discovered this alternative effect of the chemotherapy drug. The finding that paclitaxel modulates immune response opens up new prospects for the use of this drug," said Carlos Wagner Wanderley, first author of the article. If the discovery is confirmed in ...
Chemical Conjugation of Muramyl Dipeptide and Paclitaxel to Explore the Combination of Immunotherapy and Chemotherapy for Cancer 喜欢 0 阅读量: 19 作者: 刘刚 摘要: Paclitaxel (Taxol ) conjugated to muramyl dipeptide (MDP) is described. Biological testing showed that the conjugation of MDP at 2‘-...
Little is yet known about this, as immunotherapy is still in the research stage. The immune effect of treatment on cancer patients is not straightforward, and the “window period” of immunotherapy combined with chemotherapy also remains unclear. One study investigated the immunogenicity of CP-...
Background : Metastatic triple-negative breast cancer (mTNBC) is associated with poor prognosis, and chemotherapy remains the mainstay of treatment. Cancer immunotherapy represents a promising treatment approach for mTNBC, which is chara... S Adams,J Diamond,E Hamilton,... - 《Cancer Research》 ...
Paclitaxel (PTX) is widely used for treating several cancers, including breast, ovarian, lung, esophageal, gastric, pancreatic, and neck cancers. Despite its clinical utility, cancer recurrence frequently occurs in patients due to the development of resistance to PTX. Resistance mechanisms in cancer ...
Chemotherapy in combination with immunotherapy has gradually shown substantial promise to increase T cell infiltration and antitumor efficacy. However, paclitaxel in combination with immune checkpoint inhibitor targeting PD-1/PD-L1 was only used to treat a small proportion of metastatic triple-negative bre...
The anti-tumor properties of Toll-like receptor (TLR) 9 agonist CpG oligodeoxynucleotides (ODN) are enhanced by combinations with several cytotoxic chemotherapy regimens. The mechanisms of this added benefit, however, remain unclear. We now report that, similar to the depletion of regulatory T cell...
Cell division is part of the cell cycle, whether the cells are normal or cancerous. Chemotherapy is most effective at killing cells that are rapidly dividing3. Paclitaxel is a microtubule-stabilising drug that is approved as an anti-cancer agent in monotherapy or combination therapy for the ...